Phase II trial of nivolumab and axitinib in mucosal melanoma

2 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Sarah Lochrin, MBBCh, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a Phase II trial (NCT03602547) of nivolumab plus axitinib in patients with unresectable or advanced mucosal melanoma. The combination showed meaningful clinical activity and manageable safety, including in a non-Chinese population. For those progressing on doublet therapy, the addition of either ipilimumab or stereotactic body radiotherapy (SBRT) was evaluated in a pilot setting and appeared tolerable. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next